Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986337 in Healthy Participants
NCT04550195Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986337 in idiopathic pulmonary fibrosis (IPF) (13 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events up to 30 days, Incidence of Serious Adverse Events up to 81 days and 14 more. Started Sep 2020; status: completed.
02
Drugs
BMS-986337
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04550195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550195.